Navigation Links
ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System
Date:11/5/2009

EDINA, Minn., Nov. 5 /PRNewswire/ -- ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today announced that it has received 510(k) clearance from the US Food and Drug Administration for its new GLUCOCARD Vital blood glucose monitoring system.

The new meter and strip platform, which ARKRAY will make available for distribution in early December, is expected to be a significant complement to the existing GLUCOCARD line of products, and will be ideal for the home medical equipment (HME), durable medical equipment (DME), mail order and managed care markets.

"We're very excited about the latest addition to our GLUCOCARD brand," said Jonathan Chapman, President of ARKRAY, USA. "The Vital meets all of ARKRAY's rigorous design and performance standards. And we can offer it at a price point that will make it an ideal solution for our customers to use in competitive bidding."

The new GLUCOCARD Vital meter and strip platform is highly accurate, auto-coded, requires only 0.5 microliter of blood, holds 250 dowloadable tests in its memory and has a glucose oxydase (GO) strip chemistry that is not affected by interferences that cause testing errors in other common test strips.

The Vital, along with all GLUCOCARD brands, are backed by ARKRAY's unique YouChoose((TM)) wellness program, a comprehensive education and support system that includes printed tools, videos, recipes and an integrated website designed to help patients manage their diabetes.

About ARKRAY USA

ARKRAY manufactures and distributes high-quality, cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry. ARKRAY invests heavily in R&D and has a strong commitment to high-quality products. For patients, this means access to cutting-edge, reliable products without sacrificing quality, and exceptional customer service.

For more information:

www.glucocardusa.com

SOURCE ARKRAY, Inc.


'/>"/>
SOURCE ARKRAY, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 Research and Markets has announced ... report to their offering. ... The report forecasts the global optical transceiver market to ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
(Date:12/9/2016)... Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged ... rare diseases, today announced that senior management will participate in a ... at the InterContinental Barclay Hotel in New York City ... About aTyr Pharma ... aTyr Pharma is engaged in the discovery ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
Breaking Medicine Technology:
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
Breaking Medicine News(10 mins):